Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Needle-Free COVID-19 vaccine shows promise in early trial

NCT ID NCT06851611

Vaccine Sponsor: Rokote Laboratories Finland Oy Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed Phase 1 trial tested a nasal COVID-19 vaccine called COV2 in 40 healthy adults aged 18-75. The study compared two dose levels (low and high) and two administration methods (nasal drops vs. spray) to see which is safest and best at boosting immunity. Participants included both people who had prior COVID-19 vaccines and those who had never been vaccinated.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
COV2 nasal COVID-19 vaccine
What this could lead to
If successful, this could lead to a needle-free COVID-19 booster that is easier to administer and may better protect against variants.
What could go wrong
This is a small, early-phase trial focused on safety and immune response, not on preventing infection. The vaccine may not work as hoped in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

40 people

The number who actually took part.

Started

Jan 2025

Finished

Jun 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria 1. Has voluntarily signed the written informed consent 2. 18-75 years old 3. Good general health 4. a) Prior vaccination with at least two doses of any COVID-19 vaccine, OR b) No prior COVID-19 vaccination Exclusion Criteria 1. Pregnant, planning to become pregnant or breastfeeding women 2. COVID-19 infection within the last nine (9) months 3. Any other vaccination within the last two (2) months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID19, SARS-CoV-2 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

COVID-19 prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID19, SARS-CoV-2

Contacts and locations

Locations

  • Kuopio University Hospital

    Kuopio, Northern Savonia, 70210, Finland